Omnicell (NASDAQ:OMCL) Stock Rating Lowered by StockNews.com

Omnicell (NASDAQ:OMCL) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Thursday.

Several other research firms have also commented on OMCL. Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and boosted their price objective for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research note on Friday, August 23rd. Wells Fargo & Company boosted their price objective on shares of Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Benchmark reiterated a “buy” rating and set a $38.00 price objective on shares of Omnicell in a research note on Monday, July 15th. Finally, Bank of America boosted their price objective on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Omnicell has a consensus rating of “Hold” and a consensus price target of $37.83.

Omnicell Price Performance

Shares of OMCL opened at $44.62 on Thursday. The company has a 50 day moving average price of $39.21 and a 200-day moving average price of $32.24. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $53.37. The stock has a market capitalization of $2.05 billion, a PE ratio of -97.00, a PEG ratio of 47.22 and a beta of 0.83. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The company’s revenue was down 7.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.29 EPS. Equities analysts predict that Omnicell will post 0.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of OMCL. Algert Global LLC increased its stake in shares of Omnicell by 9.8% in the second quarter. Algert Global LLC now owns 51,942 shares of the company’s stock worth $1,406,000 after acquiring an additional 4,617 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Omnicell by 6.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,459 shares of the company’s stock worth $635,000 after acquiring an additional 1,360 shares during the period. Deerfield Management Company L.P. Series C increased its stake in shares of Omnicell by 238.4% in the second quarter. Deerfield Management Company L.P. Series C now owns 31,474 shares of the company’s stock worth $852,000 after acquiring an additional 22,174 shares during the period. AQR Capital Management LLC increased its stake in shares of Omnicell by 10.3% in the second quarter. AQR Capital Management LLC now owns 49,071 shares of the company’s stock worth $1,328,000 after acquiring an additional 4,572 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of Omnicell in the second quarter worth $1,623,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.